Takeda(TAK) - 2026 Q3 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Revenue for the nine-month period was just over JPY 3.4 trillion, a decrease of 3.3% or -2.8% at constant exchange rate [11] - Core Operating Profit was JPY 971.6 billion, a year-on-year decrease of 3.4% at both actual effects and constant exchange rate [11] - Reported operating profit was JPY 422.4 billion, an increase of 1.2% [12] - Core EPS was JPY 428, and reported EPS was JPY 137 [12] - Adjusted free cash flow was JPY 625.9 billion, even after a $1.2 billion upfront payment to Innovent Biologics [12] Business Line Data and Key Metrics Changes - Growth and launch products represented over 50% of total revenue and grew 6.7% at constant exchange rate [12] - In GI, Entyvio grew 7.4% at constant exchange rate, with strong growth in Q3 due to a one-time gross-to-net drop [12][13] - Takhzyro in rare diseases slowed to 2.4% growth at constant exchange rate, impacted by new competing products in the U.S. [13] - Immunoglobulin growth was 4.3% year to date, driven by subcutaneous IG products [14] - Qdenga growth accelerated to 22.1%, primarily driven by Brazil [14] Market Data and Key Metrics Changes - Entyvio Pen is now on the formulary with all three large pharmacy benefit managers, achieving commercial coverage of more than 80% [13] - The impact of Medicare Part D redesign in the U.S. has affected IVIG sales, which are expected to normalize in Q4 [14] - Albumin growth returned to 1.3%, slower than expected due to softening demand in China [14] Company Strategy and Development Direction - The company is preparing for significant new product launches, focusing on oveporexton, rusfertide, and zasocitinib, expected to launch over the next 18 months [6][9] - The late-stage pipeline includes eight programs with the potential to transform the standard of care [10] - The company is committed to maintaining operational efficiency while investing in R&D for future growth [17] Management's Comments on Operating Environment and Future Outlook - Management revised revenue guidance to low single-digit decline at constant exchange rate due to stronger than anticipated Vyvanse generic erosion [18] - The company maintains full-year guidance for core operating profit and core EPS, emphasizing cost discipline [18] - Management expressed confidence in the potential of new product launches to drive future growth despite current challenges [20][41] Other Important Information - This earnings call marked Christophe Weber's last as a main presenter, with Julie Kim set to take over as CEO [29] - The company is undergoing organizational changes to enhance competitiveness and speed in preparation for multiple launches [31][55] Q&A Session Summary Question: Thoughts on next fiscal year and dividend policy - Management indicated it is too early to provide guidance for the next fiscal year, with the budget being finalized [39] - The company aims to maintain a progressive dividend policy, evaluating core EPS and cash flow to decide on potential increases [42] Question: Zasocitinib phase II outcomes and safety data - Data from UC and Crohn's disease phase II studies are expected this year, with ongoing studies assessing higher doses for efficacy [44][46] Question: Impact of MFN and organizational changes - Management does not support MFN, emphasizing that price controls could hinder future innovation [53] - Organizational changes focus on enhancing U.S. marketing and maintaining a strong oncology business unit [55] Question: Entyvio sales trends and IRA impact - Q3 sales performance was strong, with improved coverage in the U.S. [60] - The company is preparing for potential price negotiations under the IRA, with uncertainty regarding the extent of price cuts [62][63] Question: Takhzyro growth and competitive impact - Takhzyro continues to be the gold standard for HAE patients, but recent competitive entrants have impacted new starts [67] - Long-term efficacy data supports Takhzyro's market position despite current challenges [68]